152 related articles for article (PubMed ID: 20531293)
1. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Al-Dayel F; Bu R; Bavi P; Al-Kuraya KS
Lab Invest; 2010 Sep; 90(9):1346-56. PubMed ID: 20531293
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Bu R; Ahmed SO; Ajarim D; Al-Dayel F; Bavi P; Al-Kuraya KS
Mol Cancer Ther; 2010 May; 9(5):1244-55. PubMed ID: 20423996
[TBL] [Abstract][Full Text] [Related]
3. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
4. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
5. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling.
Hussain AR; Uddin S; Ahmed M; Bu R; Ahmed SO; Abubaker J; Sultana M; Ajarim D; Al-Dayel F; Bavi PP; Al-Kuraya KS
J Pathol; 2010 Oct; 222(2):180-90. PubMed ID: 20632385
[TBL] [Abstract][Full Text] [Related]
7. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
[TBL] [Abstract][Full Text] [Related]
8. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
[TBL] [Abstract][Full Text] [Related]
9. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
[TBL] [Abstract][Full Text] [Related]
10. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
11. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
13. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
Uddin S; Bu R; Ahmed M; Hussain AR; Ajarim D; Al-Dayel F; Bavi P; Al-kuraya KS
Leuk Lymphoma; 2010 Jul; 51(7):1305-14. PubMed ID: 20443680
[TBL] [Abstract][Full Text] [Related]
14. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
[TBL] [Abstract][Full Text] [Related]
15. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.
Chang CC; McClintock S; Cleveland RP; Trzpuc T; Vesole DH; Logan B; Kajdacsy-Balla A; Perkins SL
Am J Surg Pathol; 2004 Apr; 28(4):464-70. PubMed ID: 15087665
[TBL] [Abstract][Full Text] [Related]
17. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Muppidi JR; Schmitz R; Green JA; Xiao W; Larsen AB; Braun SE; An J; Xu Y; Rosenwald A; Ott G; Gascoyne RD; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Vaidehi N; Staudt LM; Cyster JG
Nature; 2014 Dec; 516(7530):254-8. PubMed ID: 25274307
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
20. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.
Richards KL; Motsinger-Reif AA; Chen HW; Fedoriw Y; Fan C; Nielsen DM; Small GW; Thomas R; Smith C; Dave SS; Perou CM; Breen M; Borst LB; Suter SE
Cancer Res; 2013 Aug; 73(16):5029-39. PubMed ID: 23783577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]